Eramet shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend. Investors have an opportunity to buy the stock and target the € 145.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
As regards fundamentals, the enterprise value to sales ratio is at 1.01 for the current period. Therefore, the company is undervalued.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past twelve months, EPS forecast has been revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The tendency within the weekly time frame is positive above the technical support level at 69.15 EUR
Stock prices approach a strong long-term resistance in weekly data at EUR 124.2.
Technically, the stock approaches a strong medium-term resistance at EUR 130.5.
As estimated by analysts, this group is among those businesses with the lowest growth prospects.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Recevoir les alertes
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.